Which test is utilized to screen resistance to fluoroquinolones and second-line injectables?

The test utilized to screen for resistance to fluoroquinolones and second-line injectables is the Second Line Lateral Flow Assay (LPA). This test is specifically designed to detect mutations in the genes associated with resistance to these medications, which are critical in the treatment of multidrug-resistant tuberculosis (MDR-TB).

Fluoroquinolones and second-line injectables are essential components of treatment regimens for patients with resistant strains of tuberculosis, making it crucial to identify resistance mechanisms early in the clinical setting. The Second Line LPA assesses specific genetic markers that are linked to resistance, thus enabling healthcare providers to tailor treatment plans effectively.

Other tests like TB LAMP, GeneXpert MTB/RIF, and First Line LPA serve different purposes. For instance, TB LAMP is used for the rapid detection of tuberculosis but does not specifically identify drug resistance patterns. GeneXpert MTB/RIF primarily focuses on detecting Mycobacterium tuberculosis and its rifampicin resistance, while the First Line LPA is designed for assessing resistance to first-line anti-TB drugs. Therefore, the Second Line LPA is uniquely equipped to address resistance to fluoroquinolones and second-line injectables, making it the correct choice in this